您正在下载...
《Novel Combined Response Endpoint Shows that Belimumab (Fully Human Monoclonal Antibody to B-Lymphocyte Stimulator [BLyS]) Improves or Stabilizes SLE Disease Activity in a Phase 2 Trial》


False